Trifluridine/tipiracil hydrochloride mixture TAS-102|cas:733030-01-8|西域试剂

Trifluridine/tipiracil hydrochloride mixture TAS-102,99.99%

产品编号：Bellancom-16478| CAS NO：733030-01-8| 分子式：C₁₀H₁₁F₃N₂O₅.1/2C₉H₁₁ClN₄O₂.1/2HCl| 分子量：435.76

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-16478	￥650.00	杭州北京（现货）
Bellancom-16478	￥995.00	杭州北京（现货）
Bellancom-16478	￥3040.00	杭州北京（现货）
Bellancom-16478	￥4864.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Trifluridine/tipiracil hydrochloride mixture TAS-102

产品介绍

Trifluridine/tipiracil hydrochloride mixture (TAS-102) 是一种有效且具有口服活性的核苷类抗肿瘤剂。Trifluridine/tipiracil hydrochloride mixture (TAS-102) 的组成是 1:0.5 的混合物 (以摩尔计) α,α,α-三氟胸苷 (FTD) 和胸苷磷酸化酶抑制剂 (TPI)。Trifluridine/tipiracil hydrochloride mixture (TAS-102) 主要通过抑制胸苷酸合酶 (TS) 和掺入 DNA 来显示抗肿瘤活性。

生物活性

Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a potent and orally active nucleoside antitumor agent. The composition of Trifluridine/tipiracil hydrochloride mixture (TAS-102) is a 1:0.5 mixture (on a molar basis) of alpha,alpha,alpha-tri-fluorothymidine (FTD) and thymidine phosphorylase inhibitor (TPI). Trifluridine/tipiracil hydrochloride mixture (TAS-102) shows the antitumor activity mainly via the inhibition of thymidylate synthase (TS) and incorporation into DNA.

体外研究

体内研究

Trifluridine/tipiracil hydrochloride mixture (150 mg/kg/day; p.o.; twice a day for 14 days) prevents body weight loss and reduces the relative tumor volume in colorectal cancer and gastric cancer mice models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice bearing KM12C, KM12C/5-FU, DLD-1, DLD-1/5-FU, and SC-2 cells
Dosage:	150 mg/kg/day
Administration:	p.o.; twice a day for 14 days
Result:	Prevented body weight loss and reduced the relative tumor volume in colorectal cancer and gastric cancer mice models.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male nude mice bearing KM12C, KM12C/5-FU, DLD-1, DLD-1/5-FU, and SC-2 cells
Dosage:	150 mg/kg/day
Administration:	p.o.; twice a day for 14 days
Result:	Prevented body weight loss and reduced the relative tumor volume in colorectal cancer and gastric cancer mice models.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (229.48 mM; Need ultrasonic)

DMF : 20 mg/mL (45.90 mM; Need ultrasonic)

DMSO : 2.34 mg/mL (5.37 mM; Need ultrasonic and warming)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2948 mL	11.4742 mL	22.9484 mL
5 mM	0.4590 mL	2.2948 mL	4.5897 mL
10 mM	0.2295 mL	1.1474 mL	2.2948 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： Saline
Solubility: 100 mg/mL (229.48 mM); Clear solution; Need ultrasonic
2.

请依序添加每种溶剂： PBS
Solubility: 50 mg/mL (114.74 mM); Clear solution; Need ultrasonic